GleamWall
中文EN

CNBX CNBX Pharmaceuticals Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1343009 · Fiscal year ends 08/31

Financial factors as of 2026-02-28 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-24.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,121.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets17,104.8%
Debt / equity—
Current ratio0.01x
Interest coverage-6.65x

Cash quality & payout

Operating cash flow / net income0.43x
Accruals ratio-638.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-08-31FY20242024-08-31
Income statement
Revenue$0$130,074
R&D expense$0$194,788
SG&A expense$271,691$518,426
Operating income-$271,691-$583,139
Interest expense$39,819—
Net income-$313,976-$695,198
EBITDA-$271,691-$510,819
EPS (basic)0.00-0.02
EPS (diluted)0.00-0.02
Weighted avg. shares (diluted)90.65M30.25M
Banking
Net interest income-$39,813-$16,798
Balance sheet
Cash & equivalents$15,111$26,416
Current assets$18,437$31,383
PP&E, net$0$0
Total assets$18,437$31,383
Current liabilities$2.51M$2.51M
Short-term debt$0—
Total liabilities$2.51M$2.51M
Shareholders' equity-$2.50M-$2.48M
Shares outstanding553.96M31.11M
Cash flow statement
Operating cash flow-$171,305-$244,269
Investing cash flow$0$113,477
Financing cash flow$160,000$27,512
Depreciation & amortization$0$72,320
Stock-based compensation$0$139,720

Free plan shows the latest 2 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.